Ocular Therapeutix (OCUL) EBT (2013 - 2026)

Ocular Therapeutix's EBT history runs 14 years deep, the most recent figure standing at -$90.1 million for Q1 2026.

• In Q1 2026, EBT fell 42.79% year-over-year to -$90.1 million; the TTM figure through Mar 2026 stood at -$290.5 million (down 47.9% YoY), while the FY2025 annual figure was -$263.5 million, down 59.62% from the prior year.
• EBT was -$90.1 million for Q1 2026 at Ocular Therapeutix, down from -$65.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$19.5 million in Q1 2022 to a low of -$90.1 million in Q1 2026.
• Historically, EBT has averaged -$40.8 million across 5 years, with a median of -$31.7 million in 2024.
• The sharpest annual moves came in 2022 and 2024: EBT grew 10.95% in 2022, then plunged 115.51% in 2024.
• A 5-year view of EBT shows it stood at -$20.8 million in 2022, then fell by 9.42% to -$22.7 million in 2023, then slumped by 115.51% to -$49.0 million in 2024, then plunged by 33.13% to -$65.2 million in 2025, then tumbled by 38.04% to -$90.1 million in 2026.
• The last three EBT figures came in at -$90.1 million (Q1 2026), -$65.2 million (Q4 2025), and -$68.0 million (Q3 2025), per Business Quant data.